ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Functions of Urokinase and Its Receptor in Pathological Tissues of Patients with Gastric Cancer

DOI:10.31550/1727-2378-2019-158-3-54-59
Bibliography link: Kit O.I., Frantsiyants E.M., Kozlova L.S., Dzhenkova E.A., Soldatkina N.V., Samoylenko N.S. Functions of Urokinase and Its Receptor in Pathological Tissues of Patients with Gastric Cancer. Doctor.Ru. 2019; 3(158): 54–59. DOI: 10.31550/1727-2378-2019-158-3-54-59
12 April 17:33

Study Objective: To study the content of antigenic urokinase (uPA-AG), active urokinase (uPA-act) and urokinase receptor (uPAR) in gastric adenocarcinoma, its perifocal area, epiploon and peritoneum in patients with and without metastases (mts) in peritoneum and epiploon.

Study Design: Comparative study.

Materials and Methods. Examination data of 62 patients were studied. Group 1 included 22 patients with gastric cancer T3-4аN0-3M1 with metastases in peritoneum and epiploon, group 2 comprised 24 patients with gastric cancer T3-4аN0-3M0 without metastases. Control group was 17 patients with non-cancer diseases: 14 (82.3%) subjects underwent cholecystectomy because of cholecystitis, 3 (17.7%) subjects had hernioplasty because of hernia.

Gastric adenocarcinoma tissue, its perifocal area, epiploon and peritoneum taken intraoperatively were studied. uPA-AG, uPA-act, uPAR levels were determined using standard immunoenzymatic assays.

Study Results: In gastric adenocarcinoma tissue with mts, uPAR and uPA-act are higher, and non-metastatic tumours demonstrate higher uPA-AG level as compared to perifocal tumour region. In metastatic adenocarcinoma, uPARwas higher and uPA-AG was lower than in non-metastatic tumour with comparable uPA-act level in tumours with and without metastases.

The study results for epiploon and peritoneum tissues in patients with gastric cancer showed that uPAR, uPA-act and uPA-AG were statistically different from those in patients with benign tumours (р < 0.05). In epiploon with gastric cancer metastases, uPAR level was higher 23.5-fold, and in non-metastatic tumours it was 3.2 times higher. uPA-act value was statistically higher with metastases (4.6-fold). uPA-AG was significantly lower in both cases, but in metastatic cancer it was 2.6 times higher than in patients without metastases. As far as peritoneum is concerned, in metastatic and non-metastatic gastric cancer, uPAR level was 15.3 times and 5.9 times higher than in controls. uPA-AG was 1.4-fold lower in both cases as compared to controls.

Conclusion: Gastric adenocarcinoma releases uPAR and uPA; the uPAR level depend on metastases in epiploon and peritoneum. In epiploon and peritoneum, uPAR and uPA-act levels are higher in case of metastatic cancer. uPAR may be a sign of premetastatic niche formation in peritoneal tissues.

The authors declare that they do not have any conflict of interests.

O.I. Kit Rostov Scientific and Research Oncology Institute of the Ministry of Health of Russia; 63 14-ya liniya, Rostov-on-Don, Russian Federation 344037. E-mail: super.gormon@yandex.ru

E.M. Frantsiyants Rostov Scientific and Research Oncology Institute of the Ministry of Health of Russia; 63 14-ya liniya, Rostov-on-Don, Russian Federation 344037. E-mail: super.gormon@yandex.ru

L.S. Kozlova Rostov Scientific and Research Oncology Institute of the Ministry of Health of Russia; 63 14-ya liniya, Rostov-on-Don, Russian Federation 344037. E-mail: super.gormon@yandex.ru

E.A. Dzhenkova Rostov Scientific and Research Oncology Institute of the Ministry of Health of Russia; 63 14-ya liniya, Rostov-on-Don, Russian Federation 344037. E-mail: super.gormon@yandex.ru

N.V. Soldatkina Rostov Scientific and Research Oncology Institute of the Ministry of Health of Russia; 63 14-ya liniya, Rostov-on-Don, Russian Federation 344037. E-mail: super.gormon@yandex.ru

N.S. Samoylenko Rostov Scientific and Research Oncology Institute of the Ministry of Health of Russia; 63 14-ya liniya, Rostov-on-Don, Russian Federation 344037. E-mail: super.gormon@yandex.ru

Доктор.ру
12 April 17:33
LITERATURE
  1. Кит О.И. Нейроэндокринные, клинические и молекулярно-биологические аспекты рака желудка. Ростов-на-Дону: ЗАО «Ростиздат»; 2012. 241 с. [Kit O.I. Neiroendokrinnye, klinicheskie i molekulyarno-biologicheskie aspekty raka zheludka. Rostov-na-Donu: ZAO “Rostizdat”; 2012. 241 s. (in Russian)]
  2. Pascual G., Domínguez D., Benitah S.A. The contributions of cancer cell metabolism to metastasis. Dis. Model. Mech. 2018; 11(8): dmm032920. DOI: 10.1242 / dmm.032920
  3. Tustumi F., Bernardo W.M., Dias A.R., Ramos M.F., Cecconello I., Zilberstein B. et al. Detection value of free cancer cells in peritoneal washing in gastric cancer: a systematic review and meta-analysis. Clinics (Sao Paulo). 2016; 71(12): 733–45. DOI: 10.6061/clinics/2016(12)10
  4. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011; 11(10): 702–11. DOI: 10.1038/nri3064
  5. Tsai J.H., Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes. Dev. 2013; 27(20): 2192–206. DOI: 10.1101/gad.225334.113
  6. Oskarsson T., Massagué J. Extracellular matrix players in metastatic niches. EMBO J. 2012; 31(2): 254–6. DOI: 10.1038/emboj.2011.469
  7. Yadav A.S., Pandey P.R., Butti R., Radharani N.N.V., Roy S., Bhalara S.R. et al. The biology and therapeutic implications of tumor dormancy and reactivation. Front. Oncol. 2018; 8: 72. DOI: 10.3389/fonc.2018.00072
  8. Brungs D., Chen J., Aghmesheh M., Vine K.L., Becker T.M., Carolan M.G. et al. The urokinase plasminogen activation system in gastro-esophageal cancer: a systematic review and meta-analysis. Oncotarget. 2017; 8(14): 23099–109. DOI: 10.18632/oncotarget.15485
  9. Gonias S.L., Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front. Pharmacol. 2015; 6: 154. DOI: 10.3389/fphar.2015.00154
  10. Kanda M., Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J. Gastroenterol. 2016; 22(30): 6829–40. DOI: 10.3748/wjg.v22.i30.6829
  11. Dass K., Ahmad A., Azmi A.S., Sarkar S.H., Sarkar F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 2008; 34(2): 122–36. DOI: 10.1016/j.ctrv.2007.10.005
  12. Mahmood N., Mihalcioiu C., Rabbani S.A. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front. Oncol. 2018; 8: 24. DOI: 10.3389/fonc.2018.00024
  13. Ranson M., Andronicos N.M. Plasminogen binding and cancer: promises and pitfalls. Fron. Biosci. 2003; 8: s294–304.
  14. Mazzieri R., Pietrogrande G., Gerasi L., Gandelli A., Colombo P., Moi D. et al. Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of Notch1. Cancer Res. 2015; 75(22): 4895–909. DOI: 10.1158/0008-5472.CAN-15-0378
  15. Schuliga M. The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm. 2015; 2015: 437695. DOI: 10.1155/2015/437695
  16. Laufs S., Schumacher J., Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle. 2006; 5(16): 1760–71. DOI: 10.4161/cc.5.16.2994
  17. Llinas P., Le Du M.H., Gårdsvoll H., Danø K., Ploug M., Gilquin B. et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005; 24(9): 1655–63. DOI: 10.1038/sj.emboj.7600635
  18. Lund I.K., Illemann M., Thurison T., Christensen I.J., Høyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr. Drug Targets. 2011; 12(12): 1744–60.
  19. Laerum O.D., Ovrebo K., Skarstein A., Christensen I.J., Alpízar-Alpízar W., Helgeland L. et al. Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int. J. Cancer. 2012; 131(3): 558–69. DOI: 10.1002/ijc.26382
  20. Alpizar-Alpizar W., Christensen I.J., Santoni-Rugiu E., Skarstein A., Ovrebo K., Illemann M. et al. Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma. Int. J. Cancer. 2012; 131(4): E329–36. DOI: 10.1002/ijc.26417
  21. Ranson M. The plasminogen activation system in pathology: use in prognosis and therapy. Curr. Drug Targets. 2011; 12(12): 1709–10.
  22. Chen J.S., Chang L.C., Wu C.Z., Tseng T.L., Lin J.A., Lin Y.F. et al. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. J. Biomed. Sci. 2016; 23: 24. DOI: 10.1186/s12929-016-0242-7
  23. Chen J.S., Chang L.C., Wu C.Z., Tseng T.L., Lin J.A., Lin Y.F. et al. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. J. Biomed. Sci. 2016; 23: 24. DOI: 10.1186/s12929-016-0242-7 23. Mikuła-Pietrasik J., Uruski P., Tykarski A., Książek K. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol. Life Sci. 2018; 75(3): 509–25. DOI: 10.1007/s00018-017-2663-1
  24. Pavón M.A., Arroyo-Solera I., Céspedes M.V., Casanova I., León X., Mangues R. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 2016; 7(35): 57351–66. DOI: 10.18632/ONCOTARGET.10344
  25. Кит О.И., Франциянц Е.М., Козлова Л.С., Росторгуев Э.Е., Балязин-Парфенов И.В., Погорелова Ю.А. Система регуляции плазминогена в различных опухолях головного мозга. Вопр. нейрохирургии им. Н.Н. Бурденко. 2017; 81(2): 22–7. [Kit O.I., Frantsiyants E.M., Kozlova L.S., Rostorguev E.E., Balyazin-Parfenov I.V., Pogorelova Yu.A. Sistema regulyatsii plazminogena v razlichnykh opukholyakh golovnogo mozga. Vopr. neirokhirurgii im. N.N. Burdenko. 2017; 81(2): 22–7. (in Russian)]. DOI: 10.17116/neiro201781222-27
  26. Кит О.И., Франциянц Е.М., Моисеенко Т.И., Козлова Л.С., Назаралиева Н.А., Бойко К.П. и др. Исследование каскада активации плазминогена в ткани рака шейки матки. Изв. высших учебных заведений. Северо-Кавказский регион. Естественные науки. 2017; 195-2(3–2): 51–7. [Kit O.I., Frantsiyants E.M., Moiseenko T.I., Kozlova L.S., Nazaralieva N.A., Boiko K.P. i dr. Issledovanie kaskada aktivatsii plazminogena v tkani raka sheiki matki. Izv. vysshikh uchebnykh zavedenii. Severo-Kavkazskii region. Estestvennye nauki. 2017; 195-2(3–2): 51–7. (in Russian)]. DOI: 10.23683/0321-3005-2017-3-2-51-57
  27. Франциянц Е.М., Верескунова М.И., Козлова Л.С., Моисеенко Т.И., Черникова Н.В., Гурнак В.В. и др. Факторы роста и система активации плазминогена в опухолях органов женской репродуктивной системы. Молекулярная медицина. 2017; 15(2): 55–9. [Frantsiyants E.M., Vereskunova M.I., Kozlova L.S., Moiseenko T.I., Chernikova N.V., Gurnak V.V. i dr. Faktory rosta i sistema aktivatsii plazminogena v opukholyakh organov zhenskoi reproduktivnoi sistemy. Molekulyarnaya meditsina. 2017; 15(2): 55–9. (in Russian)]
  28. Франциянц Е.М., Кит О.И., Козлова Л.С., Колесников Е.Н., Кожушко М.А., Харин Л.В. и др. Фибринолитическая система в опухоли и прилежащих тканях при плоскоклеточном раке пищевода у мужчин. Соврем. пробл. науки и образования. 2017; 2. URL: https://www.science-education.ru/ru/article/view?id=26184 (дата обращения — 14.01.2019). [Frantsiyants E.M., Kit O.I., Kozlova L.S., Kolesnikov E.N., Kozhushko M.A., Kharin L.V. i dr. Fibrinoliticheskaya sistema v opukholi i prilezhashchikh tkanyakh pri ploskokletochnom rake pishchevoda u muzhchin. Sovrem. probl. nauki i obrazovaniya. 2017; 2. URL: https://www.science-education.ru/ru/article/view?id=26184 (data obrashcheniya — 14.01.2019). (in Russian)]
  29. Kit O.I., Frantsiyants E.M., Kozlova L.S., Pogorelova Y.A., Chugunova N.S., Kolesnikov E.N. et al. Free and bound plasmin in esophageal tumors and surrounding tissues in men and women. Poster Session (Board #G18) “2017. Gastrointestinal Cancers Symposium”. January 19–21, 2017. San Francisco; 2017. #G117. Proceedings. N 84: 22.
  30. Сидоренко Ю.С., Мусиенко Н.В., Франциянц Е.М. Некоторые показатели активности протеолитической системы в ткани злокачественной опухоли и перифокальной зоны при различных локализациях рака. Вестн. Южного научного центра РАН. 2008; 4(2): 93–8. [Sidorenko Yu.S., Musienko N.V., Frantsiyants E.M. Nekotorye pokazateli aktivnosti proteoliticheskoi sistemy v tkani zlokachestvennoi opukholi i perifokal'noi zony pri razlichnykh lokalizatsiyakh raka. Vestn. Yuzhnogo nauchnogo tsentra RAN. 2008; 4(2): 93–8. (in Russian)]
  31. Lian S., Xia Y., Ung T.T., Khoi P.N., Yoon H.J., Lee S.G. et al. Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells. Mol. Carcinog. 2017; 56(2): 664–80. DOI: 10.1002/mc.22524
  32. Tang L., Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed. Pharmacother. 2013; 67(2): 179–82. DOI: 10.1016/j.biopha.2012.10.003
  33. Wu F., Catano M., Echeverry R., Torre E., Haile W.B., An J. et al. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J. Neurosci. 2014; 34(43): 14219–32. DOI: 10.1523/JNEUROSCI.5309-13.2014
  34. Жировые клетки способствуют метастазированию рака. URL: https://alloncology.com/news/4/2/ (дата обращения — 15.01.2019). [Zhirovye kletki sposobstvuyut metastazirovaniyu raka. URL: https://alloncology.com/news/4/2/ (data obrashcheniya — 15.01.2019). (in Russian)]
  35. Франциянц Е.М., Шихлярова А.И., Кучерова Т.И. Роль антиоксидантных систем мозга в механизме антиканцерогенного влияния сверхнизкочастотных магнитных полей. Вопр. онкологии. 2002; 48(2): 216–22. [Frantsiyants E.M., Shikhlyarova A.I., Kucherova T.I. Rol' antioksidantnykh sistem mozga v mekhanizme antikantserogennogo vliyaniya sverkhnizkochastotnykh magnitnykh polei. Vopr. onkologii. 2002; 48(2): 216–22. (in Russian)]
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News